Cancer is one of the leading causes of death in the world. An increasing understanding of the disease has led to a multitude of new, effective therapies in recent decades. However, only a limited number of new treatment options have been found for the treatment of diffuse glioma. Diffuse glioma therefore remains a deadly disease, for which the demand for new treatments is still very high. In this thesis, a number of subjects are investigated, namely: 1) the metabolism of brain tumors and how it is involved in the development of the the cancer, 2) how the metabolism of a specific type of glioma is altered by a mutation in a gene (IDH1 ) and 3) how this altered metabolism can be used for potential new treatment options.
Krissie Lenting (1987) obtained her master's degree in Biomedical Sciences at the Radboud University Nijmegen in 2015. In 2015 she started her PhD research in the group of Dr. William Leenders at the Departments of Pathology (Radboudumc) and Biochemistry (RIMLS). She is currently working in Medical Affairs at a pharmaceutical company.